Sensei Biotherapeutics (NASDAQ:FTH) Stock Price Down 5.5% – Time to Sell?

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) traded down 5.5% during mid-day trading on Monday . The stock traded as low as $32.38 and last traded at $32.5860. Approximately 72,708 shares were traded during mid-day trading, a decline of 69% from the average daily volume of 230,977 shares. The stock had previously closed at $34.50.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. HC Wainwright restated a “buy” rating and set a $60.00 price objective on shares of Sensei Biotherapeutics in a research note on Tuesday, August 11th. Raymond James Financial initiated coverage on shares of Sensei Biotherapeutics in a report on Friday, July 31st. They set an “outperform” rating and a $56.00 price target for the company. BTIG Research restated a “buy” rating and set a $55.00 price target on shares of Sensei Biotherapeutics in a research report on Thursday, July 16th. Wall Street Zen raised shares of Sensei Biotherapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 22nd. Finally, TD Cowen began coverage on shares of Sensei Biotherapeutics in a report on Wednesday, September 9th. They issued a “buy” rating on the stock. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Sensei Biotherapeutics presently has an average rating of “Moderate Buy” and an average target price of $56.25.

Sensei Biotherapeutics Trading Down 6.0%

The business has a 50-day simple moving average of $31.96. The firm has a market cap of $838.25 million, a P/E ratio of -0.23 and a beta of -0.28.

Sensei Biotherapeutics (NASDAQ:FTH) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($2.84) EPS for the quarter, beating analysts’ consensus estimates of ($5.04) by $2.20. Equities analysts forecast that Sensei Biotherapeutics, Inc. will post -13.69 earnings per share for the current fiscal year.

Insider Transactions at Sensei Biotherapeutics

In related news, CFO Brian C. Stephenson bought 9,391 shares of the stock in a transaction on Wednesday, June 24th. The shares were purchased at an average price of $26.13 per share, with a total value of $245,386.83. Following the purchase, the chief financial officer owned 26,804 shares in the company, valued at approximately $700,388.52. This represents a 53.93% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last three months, insiders have bought 38,505 shares of company stock valued at $952,285. Corporate insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Vivo Capital LLC acquired a new position in shares of Sensei Biotherapeutics during the first quarter valued at approximately $22,758,000. Stempoint Capital LP acquired a new stake in Sensei Biotherapeutics in the first quarter worth approximately $4,188,000. Alyeska Investment Group L.P. bought a new position in Sensei Biotherapeutics during the 2nd quarter valued at $3,610,000. Bank of America Corp DE increased its position in shares of Sensei Biotherapeutics by 10,692.5% during the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after purchasing an additional 32,719 shares during the period. Finally, Renaissance Technologies LLC increased its position in shares of Sensei Biotherapeutics by 178.2% during the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after purchasing an additional 20,525 shares during the period. 10.50% of the stock is currently owned by institutional investors.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for the treatment of cancer. The company’s research is centered on activating and directing the immune system to recognize and attack tumor cells.

Sensei’s technology platform is designed to generate Immune Modulating Antibodies, or IMAs, which are intended to stimulate anti-tumor immune responses by targeting mechanisms involved in immune regulation. Its development programs have included antibody-based therapies evaluated for solid tumors, including programs studied in combination with established checkpoint inhibitors.

The company was founded in 2018 and is based in Cambridge, Massachusetts.